CYP2C19
Genomadix, Mayo Clinic Partner on CYP2C19 Testing for Remote Care For Stroke Patients
The partnership is intended to help expand adoption of the company's rapid PCR system in sites that treat stroke patients, including through telemedicine platforms.
The company is seeing its CYP2C19 test adopted broadly as it prepares to submit a new application to the FDA for an assay targeting neurodegenerative disease.
Neurologists treating patients who present with a small stroke or transient ischemic attack are now able to get PGx results to inform their prescription of Plavix within 24 hours.
UK's NICE Recommends Genetic Testing for Therapy Selection in Stroke Patients
Clopidogrel is less effective at preventing subsequent strokes in patients with certain variations in the CYP2C19 gene and testing could aid treatment selection.
PGx-Guided Dosing Can Lead to Faster Therapeutic Blood Levels of Antidepressants
A randomized controlled trial compared cytochrome P450 genotype-based dosing of tricyclic antidepressants to usual care among patients with depression.